Literature DB >> 15517381

Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis.

Ralph Melchior1, Bernard Zabel, Jürgen Spranger, Roland Schumacher.   

Abstract

UNLABELLED: We report on an 8 years and 3 months old boy with severe idiopathic juvenile osteoporosis (IJO). Clinical features included multiple fractures, especially of the vertebrae, and neurological symptoms. Biological studies showed non-parathyroid hormone-mediated excessive bone resorption and massive urinary calcium loss. Although IJO is usually a self-limiting condition after puberty, the severity of our patient's manifestations required therapeutic intervention. Clodronate (dichloromethylene-bisphosphonate) was administered parenterally every 3 months for a period of 2 years. Dramatic clinical and biochemical improvement was noted within 2 weeks. All parameters of bone resorption normalised and no new fractures occurred. After 6 months of treatment, radiological improvement with healing of fractures and rebuilding of the vertebral plates was documented. Bone mineral density increased to normal within 1 year and growth velocity was accelerated. After 2 years, treatment was stopped at the age of 10 years and 3 months. One year later, back pain and increasing pain in the knee region recurred. A tibial fracture was evident and, again, bone mineral density was far below normal. Bisphosphonate medication was reinstituted leading to rapid improvement. No side-effects were observed.
CONCLUSION: Parenteral clodronate therapy is effective in managing severe idiopathic juvenile osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517381     DOI: 10.1007/s00431-004-1541-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Clinical evaluation of patients with idiopathic juvenile osteoporosis.

Authors:  D Chlebna-Sokół; E Loba-Jakubowska; A Sikora
Journal:  J Pediatr Orthop B       Date:  2001-07       Impact factor: 1.041

2.  [Calcitonin therapy in juvenile idiopathic osteoporosis].

Authors:  A Jelonek; Z Wyrobek; M Kruszewska; I Bromboszcz; F Zontek; Z Kolodziejska
Journal:  Chir Narzadow Ruchu Ortop Pol       Date:  1975

3.  Calcium balance in children treated with diphosphonates.

Authors:  W S Uttley; N R Belton; J Syme; H Sheppard
Journal:  Arch Dis Child       Date:  1975-03       Impact factor: 3.791

4.  Idiopathic juvenile osteoporosis.

Authors:  G E Krassas
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 5.  The use of bisphosphonates in children with osteogenesis imperfecta.

Authors:  F H Glorieux
Journal:  J Pediatr Endocrinol Metab       Date:  2001       Impact factor: 1.634

Review 6.  Use of bisphosphonate therapy for osteoporosis in childhood and adolescence.

Authors:  J A Batch; J J Couper; C Rodda; C T Cowell; M Zacharin
Journal:  J Paediatr Child Health       Date:  2003-03       Impact factor: 1.954

7.  Idiopathic juvenile osteoporosis.

Authors:  G Marhaug
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

Review 8.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor.

Authors:  N J Bishop; D M Williams; J C Compston; D M Stirling; A Prentice
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

Review 10.  New insights into the molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  8 in total

Review 1.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

2.  Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.

Authors:  Giampiero I Baroncelli; Francesco Vierucci; Silvano Bertelloni; Paola Erba; Elisa Zampollo; Maria Rita Giuca
Journal:  J Bone Miner Metab       Date:  2013-04-03       Impact factor: 2.626

Review 3.  Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients.

Authors:  Stefania Costi; Teresa Giani; Francesco Orsini; Rolando Cimaz
Journal:  Paediatr Drugs       Date:  2022-01-11       Impact factor: 3.022

4.  Effect of bisphosphonates on the rapidly growing male murine skeleton.

Authors:  Eric D Zhu; Leeann Louis; Daniel J Brooks; Mary L Bouxsein; Marie B Demay
Journal:  Endocrinology       Date:  2014-01-14       Impact factor: 4.736

5.  Radiographic and MR Imaging Findings of the Spine after Bisphosphonate Treatment, in a Child with Idiopathic Juvenile Osteoporosis.

Authors:  Olympia Papakonstantinou; Maria Sakalidou; Erato Atsali; Vasiliki Bizimi; Maria Mendrinou; Efthymia Alexopoulou
Journal:  Case Rep Radiol       Date:  2015-01-20

6.  Imbalanced Diet Deficient in Calcium and Vitamin D- Induced Juvenile Osteopenia in Rats; the Potential Therapeutic Effect of Egyptian Moghat Roots Water Extract (Glossostemon bruguieri).

Authors:  Doaa A Ghareeb; Fatma H El-Rashidy; Sherif El-Mallawany
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

7.  The boy who refused an IV: a case report of subcutaneous clodronate for bone pain in a child with Ewing Sarcoma.

Authors:  Harold Siden
Journal:  J Med Case Rep       Date:  2007-03-21

8.  Idiopathic juvenile osteoporosis: A case report and review of the literature.

Authors:  Ahmet Imerci; Umut Canbek; Sema Haghari; Levent Sürer; Muge Kocak
Journal:  Int J Surg Case Rep       Date:  2015-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.